The clinical outcome in triple-negative breast cancer (TNBC) has traditionally been considered less favorable compared to other breast cancer subtypes, mainly due to its aggressive nature, higher likelihood of recurrence, and the absence of targeted therapies like those available for hormone receptor-positive and HER2-positive breast cancers. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.